Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7567132 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part I: RO7567132 Dose Escalation With or Without Atezolizumab | EXPERIMENTAL | - |
| Part II: RO7567132 Backfill With Atezolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO7567132 and Atezolizumab | DRUG | RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort. |
Inclusion Criteria: * Male or female participants aged ≥18 years * Body weight \> 40 kilograms (kg) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 and Life expectancy of at least 12 weeks * Participants with advanced and/or metastatic solid tumors * Availability and willin...
RO7567132 is an investigational small molecule developed by Roche Holding AG for the treatment of advanced solid tumors. It is being studied both as a single agent and in combination with atezolizumab in adult patients with cancer. It is currently in Phase 1 clinical development and has not been approved for any indication.
RO7567132 is being evaluated for the treatment of cancer, specifically advanced solid tumors. The Phase 1 study enrolls adults aged 18 years and older with Cancer-Neoplasms. Because it remains investigational, RO7567132 is not approved for any use outside of clinical research.
RO7567132 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is running the clinical program for the asset, including a Phase 1 dose-escalation study in advanced solid tumors that tests the drug alone and in combination with atezolizumab.
RO7567132 is in Phase 1 clinical development. The only registered trial is a Phase 1 dose-escalation study, and no Phase 2 or Phase 3 trials have been recorded. As an investigational agent, RO7567132 has not received FDA approval and is not available outside of clinical trials.
RO7567132 is being studied in one active trial, NCT06537310, titled a dose-escalation study of RO7567132 as a single agent and in combination with atezolizumab in participants with advanced solid tumors. The study is active but not recruiting, has enrolled 34 participants, and takes place in Australia, Belgium, Canada, Denmark, and Spain.
No. RO7567132 and atezolizumab are separate agents. RO7567132 is an investigational small molecule in Phase 1 testing, while atezolizumab is an existing therapy used as the combination partner in the NCT06537310 study. The trial evaluates RO7567132 given alone and together with atezolizumab in advanced solid tumors.